Condition
Relapsed or Refractory Non-Hodgkin's Lymphoma
Total Trials
3
Recruiting
1
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
3Total
P 1 (3)
Trial Status
Terminated1
Recruiting1
Completed1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT05965505Phase 1TerminatedPrimary
Study of AXT-1003 in Adult Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas
NCT06082596Phase 1CompletedPrimary
Study of BEBT-908 in Subjects With Advanced Hematological Tumors
NCT05768529Phase 1RecruitingPrimary
Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Showing all 3 trials